EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.
EnBiotix is a product-focused bioengineering company that advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections. Through breakthrough systems and synthetic biology platforms, EnBiotix is transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant bacterial infections. These approaches have developed a robust clinical product pipeline addressing a wide range of acute and chronic infections in what is today over a $40 billion market, with the potential to significantly impact the lives of patients, caregivers, and payors worldwide.It was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 5, 2022 | Series Unknown | $3.46M | — | — | — | Detail |
Dec 29, 2021 | Convertable Note | $11M | 3 | Vectura Group | — | Detail |
Sep 26, 2019 | Series Unknown | $3.14M | — | — | — | Detail |
May 12, 2016 | Series A | — | 2 | Wired Holdings | — | Detail |
Jan 1, 2016 | Grant | — | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Vectura Group | Yes | Convertable Note |
Wired Holdings | Yes | Series A |
Sanford Biosciences | — | Convertable Note |
Cystic Fibrosis Foundation | — | Convertable Note |
Apeiron Holdings Limited | — | Series A |
EnBiotix has acquired 1 organizations. Their most recent acquisition was AMP Therapeutics - Antimicrobial Peptides on Nov 3, 2016. They acquired AMP Therapeutics - Antimicrobial Peptides for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Nov 3, 2016
AMP Therapeutics - Antimicrobial Peptides
|
Alternative Medicine | acquisition | — | Detail |